Related Experiment Video

Updated: Jul 8, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Is B-Raf a good therapeutic target for melanoma and other malignancies?

SubbaRao V Madhunapantula1, Gavin P Robertson

  • 1Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Cancer Research
|January 4, 2008
PubMed

Insights

B-Raf is a key player in the Ras/Raf/MAP kinase/extracellular signal-regulated kinase (Erk) pathway driving cancer. Despite B-Raf mutations in many cancers, clinical efficacy of targeted agents remains limited, prompting research into new strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • The mitogen-activated protein (MAP) kinase pathway, including Ras/Raf/MEK/Erk, is crucial for relaying signals that promote cancer development.
  • Mutations in this pathway occur in approximately 7% of human cancers, with B-Raf being frequently activated during tumorigenesis.
  • B-Raf is a recognized cancer target, but limited clinical efficacy of current inhibitors raises questions about its therapeutic utility.

Purpose of the Study:

  • To review recent advancements in understanding B-Raf as a therapeutic target.
  • To discuss strategies for improving B-Raf targeted therapy, including combination treatments and targeting other pathway components.
  • To resolve the controversy surrounding the clinical utility of B-Raf inhibition in melanoma and other cancers.

Main Methods:

  • Review of preclinical models and clinical studies.
  • Analysis of B-Raf signaling pathway and its role in cancer.
  • Evaluation of therapeutic strategies targeting B-Raf and related molecules.

Main Results:

  • B-Raf mutations are common drivers in various cancers, particularly melanoma.
  • Current B-Raf inhibitors show limited clinical efficacy, necessitating further investigation.
  • Alternative and combination therapeutic approaches are under evaluation to overcome resistance and improve outcomes.

Conclusions:

  • The therapeutic potential of B-Raf as a cancer target is still debated due to clinical efficacy challenges.
  • Developing novel B-Raf inhibitors or combination therapies is crucial for improving patient outcomes.
  • Further research is needed to fully elucidate the role of B-Raf in different malignancies and optimize treatment strategies.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...